APO RESEARCH · REPORT
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV)
Selected research
Market Structure
Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) include CSL, Biotest, Beijing Tiantan Biological Products, Shanxi Kangbao Biological Product and Taibang Biologic Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market size, projected growth trends, production technologies, key applications, and end-use industries.
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Company
CSL
Biotest
Beijing Tiantan Biological Products
Shanxi Kangbao Biological Product
Taibang Biologic Group
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Type
25ml
50ml
100ml
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Application
Hopistial
Clinic
Others
Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 25ml
- 50ml
- 100ml
Applications
- Hopistial
- Clinic
- Others
Companies covered
- CSL
- Biotest
- Beijing Tiantan Biological Products
- Shanxi Kangbao Biological Product
- Taibang Biologic Group
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Dynamics
- 2.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Trends
- 2.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Drivers
- 2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Opportunities and Challenges
- 2.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Restraints
3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Manufacturers
- 3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Manufacturers (2021-2026)
- 3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Manufacturers (2021-2026)
- 3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Manufacturers, Product Type & Application
- 3.7 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Players Market Share by Revenue in 2025
- 3.8.3 2025 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Tier 1, Tier 2, and Tier 3
4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Type
- 4.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Type Introduction
- 4.1.1 25ml
- 4.1.2 50ml
- 4.1.3 100ml
- 4.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type
- 4.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Type (2021-2032)
- 4.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Type (2021-2032)
- 4.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Type
- 4.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Type (2021-2032)
- 4.3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Market Share by Type (2021-2032)
5 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market by Application
- 5.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Application Introduction
- 5.1.1 Hopistial
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application
- 5.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Application (2021-2032)
- 5.2.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Market Share by Application (2021-2032)
- 5.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Application
- 5.3.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Application (2021-2032)
- 5.3.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Market Share by Application (2021-2032)
6 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region
- 6.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2021-2032)
- 6.2.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Region (2021-2026)
- 6.2.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region
- 7.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region
- 7.1.1 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region (2021-2026)
- 7.1.3 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue by Region (2027-2032)
- 7.1.4 Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue (2021-2032)
- 7.2.2 North America Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue (2021-2032)
- 7.3.2 Europe Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL
- 8.1.1 CSL Company Information
- 8.1.2 CSL Business Overview
- 8.1.3 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 8.1.5 CSL Recent Developments
- 8.2 Biotest
- 8.2.1 Biotest Company Information
- 8.2.2 Biotest Business Overview
- 8.2.3 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Biotest Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 8.2.5 Biotest Recent Developments
- 8.3 Beijing Tiantan Biological Products
- 8.3.1 Beijing Tiantan Biological Products Company Information
- 8.3.2 Beijing Tiantan Biological Products Business Overview
- 8.3.3 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Beijing Tiantan Biological Products Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 8.3.5 Beijing Tiantan Biological Products Recent Developments
- 8.4 Shanxi Kangbao Biological Product
- 8.4.1 Shanxi Kangbao Biological Product Company Information
- 8.4.2 Shanxi Kangbao Biological Product Business Overview
- 8.4.3 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Shanxi Kangbao Biological Product Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 8.4.5 Shanxi Kangbao Biological Product Recent Developments
- 8.5 Taibang Biologic Group
- 8.5.1 Taibang Biologic Group Company Information
- 8.5.2 Taibang Biologic Group Business Overview
- 8.5.3 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Taibang Biologic Group Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Product Portfolio
- 8.5.5 Taibang Biologic Group Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Value Chain Analysis
- 9.1.1 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Production Mode & Process
- 9.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Distributors
- 9.2.3 Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst